Adjuvant Merkel Cell (ECOG-ACRIN EA6174)
- Result Type
- clinical trial
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
You are viewing results from Research and Clinical Trials.
11results found for:
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
Status: Active, Recruiting
DecisionDx-Melanoma Impact in Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes
Status: Active, Recruiting
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Status: Active, Recruiting
Study of ASTX029 in Subjects With Advanced Solid Tumors
Status: Active, Recruiting
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Pat
Status: Active, Recruiting
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
Status: Active, Recruiting
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Status: Active, Recruiting
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Status: Active, Recruiting
A PHASE II STUDY OF CONCURRENT STEREOTACTIC BODY RADIOTHERAPY WITH RELATLIMAB AND NIVOLUMAB IN PATIENTS WITH METASTATIC UVEAL MELANOMA
Status: Active, Recruiting
Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation / alteration
Status: Active, Recruiting
Check-ups, screenings and sick visits for adults and children.
Expertise and advanced technologies in all areas of medicine.
For serious accidents, injuries and conditions that require immediate medical care.
After-hours, weekend and holiday services.
Convenient walk-in care clinics for your non-urgent health needs.
We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences